Rabeprazole ER

ApprovedSmall molecule

Eisai

Rabeprazole ER is one of 150 small molecule programs targeting Dyspepsia. It is currently in Approved.

Indications

Total Trials

Active Trials

149

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyspepsiaActive, not recruiting

Duodenal UlcerActive, not recruiting

Gastric UlcerActive, not recruiting

MALT LymphomaActive, not recruiting

Gastroesophageal Reflux DiseaseActive, not recruiting

EsophagitisActive, not recruiting

GastritisActive, not recruiting

DyspepsiaPreclinical

Active, not recruiting

Duodenal UlcerPhase 2

Active, not recruiting

Gastric UlcerApproved

Active, not recruiting

MALT LymphomaPreclinical

Active, not recruiting

Gastroesophageal Reflux DiseasePhase 3

Active, not recruiting

EsophagitisPreclinical

Active, not recruiting

GastritisApproved

Active, not recruiting

Competition

Competitive Landscape

99 competitors in Dyspepsia

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Phase 3

2 2

Tofranil

Sanofi

Phase 3

1 3

Elavil

AstraZeneca

Phase 3

1 4

Rabeprazole ER

Eisai

Approved

1 5

Neurontin

VViatris Specialty LLC

Phase 3

1 6

Pamelor

SSpecgx

Phase 3

1 7

Domperidone

Johnson & Johnson

Phase 3

3 8

Xifaxan

SSalix

Phase 2

3 9

Nereus

VVanda Pharmaceuticals

Phase 2

1 10

Aciphex

Akero Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastroesophageal Reflux Disease12 trials

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Completed· Eisai logo

Eisai·Phase 3·NCT00839306·240 enrolled

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Completed· Eisai logo

Eisai·Phase 3·NCT00911534·305 enrolled

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Completed· Eisai logo

Eisai·Phase 3·NCT00658775·1,069 enrolled

Show 9 more trials

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT00855361·69 enrolled

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Completed· Eisai logo

Eisai·Phase 3·NCT00658632·1,397 enrolled

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Completed· Eisai logo

Eisai·Phase 3·NCT00165672·26 enrolled

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT00747526·51 enrolled

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Completed· Eisai logo

Eisai·Phase 3·NCT00658528·1,061 enrolled

A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00747695·31 enrolled

A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00216489·191 enrolled

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

Completed· Eisai logo

Eisai·Phase 2·NCT00132496·111 enrolled

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Completed· Eisai logo

Eisai·Phase 3·NCT00838526·240 enrolled

Efficacy and Safety3 trials

Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants

Completed·TTenNor Therapeutics (Suzhou) Limited·Phase 2·NCT06076694·80 enrolled

E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Completed· Eisai logo

Eisai·Phase 3·NCT00236197·619 enrolled

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Completed· Eisai logo

Eisai·Phase 3·NCT00236184·629 enrolled

Esophagitis3 trials

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Completed· Eisai logo

Eisai··NCT01321567·2,157 enrolled

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

Unknown status·XXuanzhu Biopharmaceutical Co., Ltd.·Phase 2·NCT05604261·156 enrolled

To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis

Completed·ZZeria Pharmaceutical·Phase 2·NCT02463643·503 enrolled

Treatment2 trials

A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms

Completed· Eisai logo

Eisai··NCT01286194·1,500 enrolled

Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT00614536·1,142 enrolled

Tics2 trials

To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

Completed·ZZeria Pharmaceutical·Phase 1·NCT02509923·54 enrolled

The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets

Completed·TTenNor Therapeutics Inc.·Phase 1·NCT06337604·20 enrolled

18 more indications

MACE2 trials

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT01990586

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fasted Conditions

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT01990378

Adult2 trials

A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)

Completed· Eisai logo

Eisai·Phase 2·NCT01202071·24 enrolled

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01101646·36 enrolled

Oral2 trials

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Completed· Takeda logo

Takeda·Phase 3·NCT02037477·20 enrolled

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05380947·13 enrolled

H Pylori Infection1 trial

Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection

Completed·TTenNor Therapeutics (Suzhou) Limited·Phase 3·NCT05857163·700 enrolled

Gastritis1 trial

A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis

Unknown status·—·Phase 4·NCT03908619·252 enrolled

Adult Subject1 trial

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects

Completed·YYungjin Pharm. Co., Ltd.·Phase 1·NCT04703868·88 enrolled

Helicobacter Pylori Infection1 trial

Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00216450·80 enrolled

MALT lymphoma1 trial

Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori

Completed· Eisai logo

Eisai··NCT01264822·108 enrolled

Fed1 trial

Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00649493·72 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00992589·344 enrolled

Gastroesophageal Reflux1 trial

Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT01018160·1,197 enrolled

Gastric Ulcer1 trial

A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium

Completed· Eisai logo

Eisai·Phase 4·NCT00125736·520 enrolled

Helicobacter Pylori Eradication1 trial

A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules

Completed·TTenNor Therapeutics (Suzhou) Limited·Phase 1/2·NCT06076681·40 enrolled

Duodenal Ulcer1 trial

A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

Completed·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 2·NCT04503629·150 enrolled

Dyspepsia1 trial

Zuojin Wan Combined With Rabeprazole or Mosapride for the Treatment of Functional Dyspepsia Combined With Depression

Not yet recruiting·NNanjing First Hospital, Nanjing Medical University·N/A·NCT06481371·120 enrolled

Infection1 trial

10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication

Unknown status·IIndonesia University·Phase 4·NCT03134378·73 enrolled

Gastric1 trial

A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT00378287·37 enrolled

Unspecified3 trials

Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00649194·72 enrolled

Effect of Proton Pump Inhibitors on Palpitations

Completed·JJordan Collaborating Cardiology Group·N/A·NCT02826408·30 enrolled

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00648349·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 45 trial records for Rabeprazole ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rabeprazole ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rabeprazole ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eisai

Rabeprazole ER

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastroesophageal Reflux Disease12 trials

Efficacy and Safety3 trials

Esophagitis3 trials

Treatment2 trials

Tics2 trials

MACE2 trials

Adult2 trials

Oral2 trials

H Pylori Infection1 trial

Gastritis1 trial

Adult Subject1 trial

Helicobacter Pylori Infection1 trial

MALT lymphoma1 trial

Fed1 trial

Safety and Efficacy1 trial

Gastroesophageal Reflux1 trial

Gastric Ulcer1 trial

Helicobacter Pylori Eradication1 trial

Duodenal Ulcer1 trial

Dyspepsia1 trial

Infection1 trial

Gastric1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News